ישראל - עברית - Ministry of Health

novartis israel ltd - epoetin alfa - תמיסה להזרקה - epoetin alfa 8000 iu / 0.8 ml - erythropoietin

ישראל - עברית - Ministry of Health

aop orphan pharmaceuticals israel ltd, israel - ropeginterferon alfa-2b - תמיסה להזרקה - ropeginterferon alfa-2b 500 mcg/ml - ropeginterferon alfa-2b

ישראל - עברית - Ministry of Health

aop orphan pharmaceuticals israel ltd, israel - ropeginterferon alfa-2b - תמיסה להזרקה - ropeginterferon alfa-2b 1000 mcg/ml - ropeginterferon alfa-2b

ישראל - עברית - Ministry of Health

unipharm ltd, israel - clopidogrel as hydrogen sulfate - טבליה - clopidogrel as hydrogen sulfate 75 mg - clopidogrel - clopidogrel - clopidogrel is indicated for the prevention of atherothrombotic events as follows : * recent mi recent stroke or established peripheral arterial disease : patients suffering from myocardial infarction (from a few days until less than 35 days ) ischaemic stroke ( from 7 days until less than 6 months) or established peripheral arterial disease. for patients with a history of recent myocardial infarction (mi) recent stroke or established peripheral arterial disease clopidogrel has been shown to reduce the rate of a combined endpoint of new ischemic stroke (fatal or not) new mi (fatal or not) and other vascular death. * acute coronary syndrome: for patients with acute coronary syndrome (non-st segment elevation acute coronary syndrome (unstable angina/non-q-wave mi) or st segment elevation acute myocardial infarction ) in combination with asa in medically treated patients eligible for thrombolytic therapy and those who are to be managed with percutaneous coronary intervention (with or without stent) or cabg . clo

ישראל - עברית - Ministry of Health

dexcel pharma technologies ltd - clopidogrel as besylate 75 mg - film coated tablets - clopidogrel - clopidogrel is indicated for the prevention of atherothrombotic events as follows:• recent mi, recent stroke or established peripheral arterial disease: patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. for patients with a history of recent myocardial infarction (mi), recent stroke or established peripheral arterial disease, clopidogrel has been shown to reduce the rate of a combined endpoint of new ischemic stroke (fatal or not), new mi (fatal or not) and other vascular death.• acute coronary syndrome: for patients with acute coronary syndrome (non-st segment elevation acute coronary syndrome (unstable angina/non-q-wave mi) or st segment elevation acute myocardial infarction), in combination with asa in medically treated patients eligible for thrombolytic therapy, and those who are to be managed with percutaneous coronary intervention (with or without stent) or cabg clopi

ישראל - עברית - Ministry of Health

taro international ltd - clopidogrel 75 mg - film coated tablets - clopidogrel - clopidogrel is indicated in adults for the prevention of atherothrombotic events as follows:patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease.patients suffering from acute coronary syndrome- non-st segment elevation acute coronary syndrome (unstable angina/non-q-wave myocardial infarction (mi)), including patients undergoing a stent replacement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy

ישראל - עברית - Ministry of Health

taro international ltd - clopidogrel 75 mg - film coated tablets - clopidogrel - clopidogrel is indicated in adults for the prevention of atherothrombotic events as follows:patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease.patients suffering from acute coronary syndrome- non-st segment elevation acute coronary syndrome (unstable angina/non-q-wave myocardial infarction (mi)), including patients undergoing a stent replacement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). - st segment elevation acute myocardial infarction, in combination with asa in medically treated patients eligible for thrombolytic therapy

ישראל - עברית - Ministry of Health

genmedix , israel - streptokinase - אבקה להכנת תמיסה לזריקה - streptokinase 1500000 iu - streptokinase - streptokinase - systemic administration: in deep vein thromboses, lung embolism, acute myocardial infarction for re-opening of coronary vessels. in acute and subacute thromboses of peripheral arteries and chronic occlusive arterial diseases, occlusion of central retinal artery or vein. local administration: in acute myocardial infarction for re-opening of coronary vessels, in acute, subacute and chronic thromboses as well as embolisms of peripheral arteries.

ישראל - עברית - Ministry of Health

ferring pharmaceuticals ltd - desmopressin acetate - תמיסה להזרקה - desmopressin acetate 15 mcg/ml - desmopressin - desmopressin - shortening/normalization/ control of bleeding in uremia, liver cirrhoses, congenital or drug induced thrombocyte dysfunction and of unknown aetiology before surgery. mild haemophilia a and mild von willebrands except type iib.

ישראל - עברית - Ministry of Health

padagis israel agencies ltd, israel - tacrolimus as monohydrate - קפסולות - tacrolimus as monohydrate 0.5 mg - tacrolimus - tacrolimus - prophylaxis of transplant rejection in liver kidney or heart allograft recipients.treatment of allograft rejection resistant to treatment with other immuonosuppressive medicinal products.